Ignite Creation Date:
2024-05-06 @ 7:59 PM
Last Modification Date:
2024-10-26 @ 3:17 PM
Study NCT ID:
NCT06203327
Status:
RECRUITING
Last Update Posted:
2024-01-17
First Post:
2023-12-25
Brief Title:
Atrophic Gastritis Predicts the Risk of Gastric Cancer
Sponsor:
Shanghai Jiao Tong University School of Medicine
Organization:
Shanghai Jiao Tong University School of Medicine
Study Overview
Official Title:
Atrophic Gastritis Predicts the Risk of Gastric Cancer a Prospective Cohort Study
Status:
RECRUITING
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Despite declining incidence rates gastric cancer GC ranks the fourth leading cause of cancer-related mortality and the fifth most common cancer worldwide with the highest incidence reported in Eastern Asia The 5-year overall survival rate of early GC exceeds 90 which was well above advanced GC Most intestinal-type GCs follow the Correa cascade-inflammationatrophy intestinal metaplasia IM dysplasia and subsequent carcinoma The presence of gastric mucosal atrophy and intestinal metaplasia are important risk factors for GC The purpose of this study was to investigate the incidence of GC attributed to atrophic gastritis in a region with high incidence of GC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None